What is Bioventus's SG&A?

Bioventus (BVS) reported SG&A of $78.33M in Q1 2026.

How has Bioventus's SG&A changed year-over-year?

Bioventus's SG&A increased by 6.6% year-over-year, from $73.5M to $78.33M.

What is the long-term trend for Bioventus's SG&A?

Over 4 years (2021 to 2025), Bioventus's SG&A has grown at a 5.4% compound annual growth rate (CAGR), from $254.25M to $314.03M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Bioventus BVS SG&A

SG&A at other companies

StrykerSYK

$2.28B-0.8%

Orthofix Medical Inc.OFIX

$134.91M+1.5%

Zimmer Biomet HoldingsZBH

$849.9M+12.0%

MedtronicMDT

$3.06B+12.4%

Organogenesis Holdings Inc.ORGO

$65.19M-10.1%

EnovisENOV

$282.81M+5.1%

Other financials

Income statement

See full

Revenue$132.1M+6.6%

Gross profit$90.8M+9.3%

Operating income$8.4M+72.8%

Net income$3.1M+218%

EPS (diluted)$0.04+200%

Balance sheet

See full

Cash & equivalents$35.8M+57.2%

Total debt$288.4M-21.2%

Total equity$188.9M+27.5%

Total assets$650.5M-5.9%

Cash flow

See full

Operating cash flow$8.9M+146%

CapEx$574.0K-30.5%

Free cash flow$8.4M+141%

Valuation

See full

Market cap$659.19M+51.7%

Enterprise value$911.76M+17.2%

P/E23.1×—

P/S1.1×+0.4×

Profitability

See full

Gross margin68.7%+1.2pp

Operating margin10%—

Net margin4.9%+3.2pp

FCF margin17.5%+13.2pp

Returns & leverage

See full

Return on equity16.9%+10.9pp

Debt / equity1.5×-0.9×

Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bioventus's SG&A?: Bioventus (BVS) reported SG&A of $78.33M in Q1 2026.
How has Bioventus's SG&A changed year-over-year?: Bioventus's SG&A increased by 6.6% year-over-year, from $73.5M to $78.33M.
What is the long-term trend for Bioventus's SG&A?: Over 4 years (2021 to 2025), Bioventus's SG&A has grown at a 5.4% compound annual growth rate (CAGR), from $254.25M to $314.03M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.